NCT03254758View on ClinicalTrials.gov

A Study of ADR-001 in Patients With Liver Cirrhosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

July 20, 2017

Primary Completion Date

April 13, 2023

Study Completion Date

April 13, 2023

Conditions
Decompensated Liver Cirrhosis
Interventions
BIOLOGICAL

Mesenchymal stem cell

"Phase1 The dose of AD-MSCs are escalated from low to mid and high step by step. Each administration is one time via intravenous infusion for one hour.~Phase2 The recommended dose of ADR-001 is administrated once a week 4 times. The administration route and time is same method with Phase 1."

Trial Locations (2)

951-8510

Niigata University Medical & Dental Hospital, Niigata

173-8610

Nihon University Itabashi Hospital, Tokyo

All Listed Sponsors
lead

Rohto Pharmaceutical Co., Ltd.

INDUSTRY

NCT03254758 - A Study of ADR-001 in Patients With Liver Cirrhosis | Biotech Hunter | Biotech Hunter